Drugs to Watch: Precision, Remission, Progression: Four Transformative Therapies Reshaping Chronic Rare Disease Management in 2026

The chronic disease and inflammation landscape is undergoing profound transformation. Rather than managing symptoms, next-generation precision therapies are increasingly targeting the root immunological drivers of disease, enabling remission discussions and halting progression across multiple therapeutic areas.

This webinar explores four groundbreaking anti-inflammatory and disease-modifying therapies that exemplify this paradigm shift:  

• the selective APRIL inhibition of VOYXACT (sibeprenlimab) addressing the immunopathology of the kidney disease IgAN;  
• the targeted oral IL-23 receptor antagonism of Icotrokinra for plaque psoriasis, challenging injectable biologics in dermatology;  
• the brain-penetrant BTK inhibition of tolebrutinib, transforming multiple sclerosis treatment;
• and the ultra-long-acting IL-5 inhibition of depemokimab redefining severe asthma management.

Through in-depth clinical and commercial analysis from leading industry specialists at Clarivate, we will examine the pivotal clinical trial evidence, competitive positioning, market impact, and the specific unmet needs each therapy addresses.  

Discover how convenient delivery systems, precision mechanisms, and disease-modifying potential are reshaping treatment algorithms—and the commercial and regulatory hurdles each must overcome to achieve blockbuster status.